MedTrace Logo

Sotatercept in Pulmonary Arterial Hypertension

NCT07140484 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension.

Participants will be asked to:

* Take Sotatercept every 21 days (±3 days)
* Each participant will be enrolled in the study for 29 Weeks
* Visit the clinic 18 times
* Have a physical exam
* Perform assessments of lung function and exercise tests
* Have an ultrasound of their heart
* Have blood draws done at regular intervals

The main objectives of the study are:

Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise.

Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.

Conditions

  • Pulmonary Artery Hypertension

Interventions

DRUG

Sotatercept

0.7mg/kg

Sponsors & Collaborators

  • Merck Canada Inc.

    collaborator INDUSTRY

  • Alberta Health services

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Jason Weatherald, MD · University of Alberta

  • Michael Stickland, PhD · University of Alberta

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-06
Primary Completion
2029-01-01
Completion
2030-01-01
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140484 on ClinicalTrials.gov